CJC-1295 with DAC is a long-acting GHRH analog designed for sustained GH/IGF-1 pathway research. Its albumin-binding DAC extension creates a multi-day pharmacodynamic profile that is clearly different from Modified GRF(1-29) / no-DAC material.

What this formula features: Albumin binding is the defining feature. In controlled human research, CJC-1295 produced sustained, dose-dependent elevations in GH and IGF-1 lasting for days, while preserving measurable pulsatile GH secretion.

Typical research readouts: Typical endpoints include multi-day GH and IGF-1 profiles, pulse frequency and amplitude, pharmacokinetic half-life, albumin binding, and cumulative endocrine response after repeated exposure. The long duration should be treated as a core experimental variable.

This product is strictly for research purposes only. Not approved for human or animal use.